Notably, 96.9% (462/477) of HER2 mutations occurred in subclonal tumours from HER2 amplification-positive patients, which was greater than the value of 82.7% (43/52) observed in HER2 amplification-negative patients (P < 0.001). Here, ERBB2 is linked to neoplasm.